142 related articles for article (PubMed ID: 22320867)
21. Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1.
Neubauer H; Clare SE; Wozny W; Schwall GP; Poznanovic S; Stegmann W; Vogel U; Sotlar K; Wallwiener D; Kurek R; Fehm T; Cahill MA
Breast Cancer Res; 2008; 10(5):R85. PubMed ID: 18922159
[TBL] [Abstract][Full Text] [Related]
22. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
[TBL] [Abstract][Full Text] [Related]
23. Oestrogen and progesterone receptors in Nigerian breast cancer: relationship to tumour histopathology and survival of patients.
Ikpatt OF; Ndoma-Egba R
Cent Afr J Med; 2003; 49(11-12):122-6. PubMed ID: 15301464
[TBL] [Abstract][Full Text] [Related]
24. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
[TBL] [Abstract][Full Text] [Related]
25. Survival of women with node negative breast cancer in the Auckland region.
Lethaby AE; Mason BH; Harvey VJ; Holdaway IM
N Z Med J; 1996 Sep; 109(1029):330-3. PubMed ID: 8862351
[TBL] [Abstract][Full Text] [Related]
26. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer.
Sáez R; Molina MA; Ramsey EE; Rojo F; Keenan EJ; Albanell J; Lluch A; García-Conde J; Baselga J; Clinton GM
Clin Cancer Res; 2006 Jan; 12(2):424-31. PubMed ID: 16428482
[TBL] [Abstract][Full Text] [Related]
27. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
Fan Y; Guan Y; Zhao WH; Li Q; Xu BH
Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993
[TBL] [Abstract][Full Text] [Related]
28. [Expression of ER, PR and cyclin D1 in breast infiltrating ductal carcinoma and their clinicopathological significance].
Wang ZB; Zhao P; Liu M; Li XH
Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(8):514-7. PubMed ID: 15949328
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of cyclooxygenase-2 is associated with a favorable prognostic phenotype in breast carcinoma.
Nakopoulou L; Mylona E; Papadaki I; Kapranou A; Giannopoulou I; Markaki S; Keramopoulos A
Pathobiology; 2005; 72(5):241-9. PubMed ID: 16374068
[TBL] [Abstract][Full Text] [Related]
30. Flt-4-positive vessel density correlates with vascular endothelial growth factor-d expression, nodal status, and prognosis in breast cancer.
Nakamura Y; Yasuoka H; Tsujimoto M; Yang Q; Imabun S; Nakahara M; Nakao K; Nakamura M; Mori I; Kakudo K
Clin Cancer Res; 2003 Nov; 9(14):5313-7. PubMed ID: 14614015
[TBL] [Abstract][Full Text] [Related]
31. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
32. Breast cancer outcomes by steroid hormone receptor status assessed visually and by computer image analysis.
Mohammed ZM; Edwards J; Orange C; Mallon E; Doughty JC; McMillan DC; Going JJ
Histopathology; 2012 Aug; 61(2):283-92. PubMed ID: 22571413
[TBL] [Abstract][Full Text] [Related]
33. Reduced nuclear expression of transcription factor AP-2 associates with aggressive breast cancer.
Pellikainen J; Kataja V; Ropponen K; Kellokoski J; Pietiläinen T; Böhm J; Eskelinen M; Kosma VM
Clin Cancer Res; 2002 Nov; 8(11):3487-95. PubMed ID: 12429639
[TBL] [Abstract][Full Text] [Related]
34. [Relationship of oncogene C-erbB2 expression to ER, PR and PS2 in breast cancer and its prognostic significance].
Yang JQ; Chen L; Xing TY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 May; 35(3):334-6, 357. PubMed ID: 15181828
[TBL] [Abstract][Full Text] [Related]
35. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
[TBL] [Abstract][Full Text] [Related]
36. A long-term survival pattern for breast cancer treated in a single institution.
Gokce T; Karadogan I; Akcay C
Indian J Cancer; 2011; 48(2):187-93. PubMed ID: 21768664
[TBL] [Abstract][Full Text] [Related]
37. Molecular Subtypes and Prognostic Factors among Premenopausal and Postmenopausal Thai Women with Invasive Breast Cancer: 15 Years Follow-up Data.
Tubtimhin S; Promthet S; Suwanrungruang K; Supaattagorn P
Asian Pac J Cancer Prev; 2018 Nov; 19(11):3167-3174. PubMed ID: 30486605
[TBL] [Abstract][Full Text] [Related]
38. Id-1 overexpression in invasive ductal carcinoma cells is significantly associated with intratumoral microvessel density in ER-negative/node-positive breast cancer.
Jang KS; Han HX; Paik SS; Brown PH; Kong G
Cancer Lett; 2006 Dec; 244(2):203-10. PubMed ID: 16469432
[TBL] [Abstract][Full Text] [Related]
39. Thrombomodulin is a new biological and prognostic marker for breast cancer: an immunohistochemical study.
Kim SJ; Shiba E; Ishii H; Inoue T; Taguchi T; Tanji Y; Kimoto Y; Izukura M; Takai S
Anticancer Res; 1997; 17(3C):2319-23. PubMed ID: 9216709
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
